PIN Pharma Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Employees
  • 1
Employees
  • Latest Deal Type
  • 2ndary - Private
  • Investors
  • 1

PIN Pharma General Information

Description

Developer of precision immune stimulants designed to link innate and adaptive immune systems. The company's stimulants target breast and colon cancer to overcome cancer-mediated immune suppression, enabling physicians to perform treatment in an enhanced way.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Primary Office
  • 55 Broadway
  • Suite 315
  • New York, NY 10006
  • United States
+1 (212) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

PIN Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Secondary Transaction - Private 01-Apr-2021 00.000 Completed Generating Revenue
1. Early Stage VC (Series A) 01-Jan-2012 00.000 00.000 000.00 Completed Generating Revenue
To view PIN Pharma’s complete valuation and funding history, request access »

PIN Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00 00 00 00 00 000
To view PIN Pharma’s complete cap table history, request access »

PIN Pharma Patents

PIN Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-9663556-B2 Treatment of cancers with immunostimulatory hiv tat derivative polypeptides Active 04-Oct-2013 0000000000 0
US-20150098960-A1 Treatment of cancers with immunostimulatory hiv tat derivative polypeptides Granted 04-Oct-2013 0000000000
US-20170274040-A1 Treatment of cancers with immunostimulatory hiv tat derivative polypeptides Granted 04-Oct-2013 0000000000
US-10159707-B2 Treatment of cancers with immunostimulatory hiv tat derivative polypeptides Active 04-Oct-2013 0000000000
JP-2016533352-A Treatment of cancer with immunostimulatory hiv tat derivative polypeptides Pending 04-Oct-2013 A61K38/162
To view PIN Pharma’s complete patent history, request access »

PIN Pharma Executive Team (4)

Name Title Board Seat Contact Info
Colin Bier Ph.D Co-Inventor, Chief Executive Officer, Chief Scientific Officer & President
Mark Smith Corporate Secretary, Chief Business Officer, Chief Finance Officer & Business Development Executive
Joshua Goldberg Co-Inventor
You’re viewing 3 of 4 executive team members. Get the full list »

PIN Pharma Board Members (3)

Name Representing Role Since
Ivica Cerina Ph.D NGN Capital Board Member 000 0000
Richard Rathmann Self Board Member 000 0000
William Gedale JD NGN Capital Chairman 000 0000
To view PIN Pharma’s complete board members history, request access »

PIN Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PIN Pharma Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Partnership Fund for New York City Venture Capital Minority 000 0000 000000 0
To view PIN Pharma’s complete investors history, request access »